ENTX — Entera Bio Ltd.
$2.92-3.31%
Last close: · regular session
Last 60 sessions
ENTX closed at $2.92 (-3.31%) on Oct 23, 2026. Active shelf registration (S-3, Aug 2026); dilution risk: high. Float: 159.3M shares. Latest SEC filing: 424B3 on Aug 28, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ENTX in the TickerWise workspace.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ Capital Market
- Employees: 18
- Website: https://www.enterabio.com
Latest SEC filings for ENTX
Latest ENTX news
- Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting Read article
- Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.